17:33 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Catabasis reports 60-week data for edasalonexent in DMD

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that edasalonexent (CAT-1004) preserved muscle function and slowed disease progression through 60 weeks of treatment in an open-label extension of the U.S. Phase I/II MoveDMD trial in steroid-naïve Duchenne muscular...
22:55 , Feb 13, 2018 |  BC Extra  |  Clinical News

Catabasis gains on 60-week DMD data

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) was up $0.31 (25%) to $1.56 on Tuesday after reporting that edasalonexent (CAT-1004) preserved muscle function and slowed disease progression through 60 weeks of treatment in an open-label extension of the...
19:09 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Catabasis' DMD candidate slows disease progression in Phase I/II

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported data from the open-label extension of the Phase I/II MoveDMD trial showing that edasalonexent (CAT-1004) slowed disease progression in boys ages 4-7 with Duchenne muscular dystrophy (DMD). The company plans...
08:57 , Oct 4, 2017 |  BC Extra  |  Clinical News

Catabasis reports DMD candidate slowed disease progression

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) gained $0.20 to $3.03 on Wednesday after it said results from the open-label extension of the Phase II MoveDMD trial showed edasalonexent (CAT-1004) slowed disease progression in boys aged 4-7 with...
18:01 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Catabasis' edasalonexent misses primary in Phase II for DMD

In April, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported data from the Phase II portion of the U.S. Phase I/II MoveDMD trial in patients ages 4-7 with Duchenne muscular dystrophy (DMD) not on corticosteroids showing that edasalonexent...
07:00 , Oct 27, 2016 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Chimeric rat-human NMDA receptors could help guide the development of selective NMDA receptor PAMs for neurological diseases. The chimeric receptors were constructed by replacing the transmembrane or ligand-binding domains of various NMDA...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

Catabasis Pharmaceuticals, Sarepta Therapeutics deal

The companies partnered to conduct mouse model research to evaluate Duchenne muscular dystrophy (DMD) therapies comprising Sarepta’s exon skipping technology and Exondys 51 eteplirsen analog with Catabasis’ edasalonexent ( CAT-1004 ), a conjugate of salicylate...
07:00 , Sep 29, 2016 |  BC Extra  |  Company News

Catabasis, Sarepta to study DMD combination

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) gained $1.77 (40%) to $6.25 Thursday after it partnered with Sarepta Therapeutics Inc. (NASDAQ:SRPT) to study a combination treatment for Duchenne muscular dystrophy. In a mouse model of DMD, the partners...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

Omega-3 phospholipids: Bridging study data

An open-label, 4-way crossover bridging study in 56 healthy volunteers showed that a single dose of 4 g oral CaPre met the primary endpoint based on EPA and DHA levels. Specifically, levels of EPA and...
08:00 , Feb 18, 2016 |  BC Innovations  |  Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral...